Symbols / XFOR
XFOR Chart
About
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical trial to evaluate the efficacy, safety, and tolerability of oral, once-daily mavorixafor with or without stable doses of G-CSF in people with congenital, acquired primary autoimmune, or idiopathic CN who are experiencing recurrent and/or serious infections. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications; and with Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand. The company is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 296.41M |
| Enterprise Value | 231.46M | Income | -95.09M | Sales | 33.98M |
| Book/sh | 2.45 | Cash/sh | 1.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 143 | IPO | — |
| P/E | — | Forward P/E | -3.12 | PEG | — |
| P/S | 8.72 | P/B | 1.38 | P/C | — |
| EV/EBITDA | -2.56 | EV/Sales | 6.81 | Quick Ratio | 5.27 |
| Current Ratio | 5.65 | Debt/Eq | 125.54 | LT Debt/Eq | — |
| EPS (ttm) | -8.92 | EPS next Y | -1.09 | EPS Growth | — |
| Revenue Growth | 215.20% | Earnings | 2026-03-24 | ROA | -33.54% |
| ROE | -156.87% | ROIC | — | Gross Margin | 83.24% |
| Oper. Margin | -12.81% | Profit Margin | -279.86% | Shs Outstand | 87.44M |
| Shs Float | 61.12M | Short Float | 3.57% | Short Ratio | 9.05 |
| Short Interest | — | 52W High | 14.70 | 52W Low | 1.35 |
| Beta | 0.43 | Avg Volume | 602.99K | Volume | 220.75K |
| Target Price | $9.33 | Recom | None | Prev Close | $3.16 |
| Price | $3.39 | Change | 7.28% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.33
Mean price target
2. Current target
$3.39
Latest analyst target
3. DCF / Fair value
$-13.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.39
Low
$5.00
High
$13.00
Mean
$9.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-05 | main | Stifel | Buy → Buy | $10 |
| 2025-11-10 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-29 | main | Stifel | Buy → Buy | $9 |
| 2025-08-13 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-05-02 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-27 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-03-26 | reit | Cantor Fitzgerald | Overweight → Overweight | $3 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-01-14 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-11-14 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-11-14 | main | Stifel | Buy → Buy | $4 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-31 | reit | Cantor Fitzgerald | Overweight → Overweight | $5 |
| 2024-04-30 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-03-22 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-12-12 | down | B. Riley Securities | Buy → Neutral | $1 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2023-05-17 | main | Stifel | Buy → Buy | $5 |
| 2023-05-05 | reit | HC Wainwright & Co. | — → Buy | $3 |
| 2023-04-10 | main | B. Riley Securities | — → Buy | $3 |
- X4 Pharmaceuticals (XFOR) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance Wed, 22 Oct 2025 07
- $XFOR stock is up 14% today. Here's what we see in our data. - Quiver Quantitative hu, 04 Dec 2025 08
- X4 Pharmaceuticals (NASDAQ: XFOR) commences equity offering; 30-day 15% option - Stock Titan hu, 23 Oct 2025 07
- XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus Fri, 05 Dec 2025 08
- X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha Mon, 01 Dec 2025 08
- Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross? - Zacks Investment Research Wed, 24 Dec 2025 08
- Will XFOR stock rally after Fed decisions - 2025 Major Catalysts & Capital Efficiency Focused Ideas - mfd.ru Fri, 20 Feb 2026 22
- X4 Pharma rallies nearly 50% after $135 mln share offering - TradingView Fri, 24 Oct 2025 07
- $XFOR stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Dec 2025 08
- X4 Pharma (NASDAQ: XFOR) closes $155.3M offering; underwriters' option fully exercised - Stock Titan Mon, 27 Oct 2025 07
- Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025 - Yahoo Finance Wed, 30 Apr 2025 07
- X4 Pharmaceuticals Stock (XFOR) Opinions on $60M Financing and Leadership Shake-Up | XFOR Stock News - Quiver Quantitative Wed, 13 Aug 2025 07
- X4 Pharmaceuticals Expands Private Placement to $85M for Rare Disease Drug Development - Stock Titan Wed, 13 Aug 2025 07
- $XFOR stock is up 42% today. Here's what we see in our data. - Quiver Quantitative hu, 24 Jul 2025 07
- X4 Pharmaceuticals Overhauls Leadership: $60M Deal Brings CTI BioPharma's $1.7B Exit Team Onboard - Stock Titan ue, 12 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 86206 | 249997.0 | — | Purchase at price 2.90 per share. | CRAIG ADAM R | Officer and Director | — | 2025-10-23 00:00:00 | D |
| 1 | 289881 | — | — | Stock Award(Grant) at price 0.00 per share. | CRAIG ADAM R | Officer and Director | — | 2025-08-14 00:00:00 | D |
| 2 | 193254 | — | — | Stock Award(Grant) at price 0.00 per share. | KIRSKE DAVID H. SR | Chief Financial Officer | — | 2025-08-14 00:00:00 | D |
| 3 | 289881 | — | — | Stock Award(Grant) at price 0.00 per share. | VOLPONE JOHN | President | — | 2025-08-14 00:00:00 | D |
| 4 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | WYZGA MICHAEL S | Director | — | 2025-06-09 00:00:00 | D |
| 5 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGIRR DAVID W J | Director | — | 2025-06-09 00:00:00 | D |
| 6 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | STEWART MURRAY | Director | — | 2025-06-09 00:00:00 | D |
| 7 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | BRIDGER GARY J | Director | — | 2025-06-09 00:00:00 | D |
| 8 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | DE CRAECKER FRANCOISE | Director | — | 2025-06-09 00:00:00 | D |
| 9 | 1500 | — | — | Stock Award(Grant) at price 0.00 per share. | WOODS KEITH | Director | — | 2025-06-09 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 22.45M | 1.49M | 464.10K | -2.73M |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -134.50M | -101.97M | -91.54M | -74.41M |
| TotalUnusualItems | 106.93M | 7.07M | 2.21M | -10.12M |
| TotalUnusualItemsExcludingGoodwill | 106.93M | 7.07M | 2.21M | -10.12M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.45M | -101.17M | -93.87M | -88.70M |
| ReconciledDepreciation | 796.00K | 419.00K | 513.00K | 499.00K |
| ReconciledCostOfRevenue | 797.00K | 0.00 | 0.00 | |
| EBITDA | -27.58M | -94.89M | -89.33M | -84.54M |
| EBIT | -28.37M | -95.31M | -89.85M | -85.04M |
| NetInterestIncome | -3.00M | -1.20M | -3.77M | -3.63M |
| InterestExpense | 8.77M | 5.78M | 3.99M | 3.64M |
| InterestIncome | 5.77M | 4.58M | 219.00K | 10.00K |
| NormalizedIncome | -121.92M | -106.76M | -95.61M | -81.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.45M | -101.17M | -93.87M | -88.70M |
| TotalExpenses | 143.96M | 107.52M | 88.08M | 75.35M |
| TotalOperatingIncomeAsReported | -36.40M | -107.52M | -87.57M | -85.11M |
| DilutedAverageShares | 6.70M | 5.93M | 2.12M | 858.30K |
| BasicAverageShares | 6.70M | 5.93M | 2.12M | 858.30K |
| DilutedEPS | -5.70 | -17.10 | -45.60 | -119.70 |
| BasicEPS | -5.70 | -17.10 | -45.60 | -119.70 |
| DilutedNIAvailtoComStockholders | -37.45M | -101.17M | -96.41M | -102.64M |
| NetIncomeCommonStockholders | -37.45M | -101.17M | -96.41M | -102.64M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 2.55M | 13.94M |
| NetIncome | -37.45M | -101.17M | -93.87M | -88.70M |
| NetIncomeIncludingNoncontrollingInterests | -37.45M | -101.17M | -93.87M | -88.70M |
| NetIncomeContinuousOperations | -37.45M | -101.17M | -93.87M | -88.70M |
| TaxProvision | 310.00K | 78.00K | 28.00K | 17.00K |
| PretaxIncome | -37.14M | -101.09M | -93.84M | -88.68M |
| OtherIncomeExpense | 107.26M | 7.63M | -1.99M | -9.70M |
| OtherNonOperatingIncomeExpenses | 332.00K | 554.00K | -4.20M | 426.00K |
| SpecialIncomeCharges | 105.00M | 0.00 | 509.00K | -9.76M |
| GainOnSaleOfPPE | 105.00M | 0.00 | 509.00K | 0.00 |
| ImpairmentOfCapitalAssets | 0.00 | 0.00 | 9.76M | |
| GainOnSaleOfSecurity | 1.93M | 7.07M | 1.70M | -366.00K |
| NetNonOperatingInterestIncomeExpense | -3.00M | -1.20M | -3.77M | -3.63M |
| InterestExpenseNonOperating | 8.77M | 5.78M | 3.99M | 3.64M |
| InterestIncomeNonOperating | 5.77M | 4.58M | 219.00K | 10.00K |
| OperatingIncome | -141.40M | -107.52M | -88.08M | -75.35M |
| OperatingExpense | 143.16M | 107.52M | 88.08M | 75.35M |
| ResearchAndDevelopment | 81.64M | 72.02M | 61.06M | 50.65M |
| SellingGeneralAndAdministration | 61.52M | 35.51M | 27.02M | 24.70M |
| GeneralAndAdministrativeExpense | 24.70M | |||
| OtherGandA | 24.70M | |||
| GrossProfit | 1.76M | 0.00 | 0.00 | |
| CostOfRevenue | 797.00K | 0.00 | 0.00 | |
| TotalRevenue | 2.56M | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 2.56M | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 5.70M | 5.58M | 4.06M | 937.59K |
| ShareIssued | 5.70M | 5.58M | 4.06M | 937.59K |
| NetDebt | 19.73M | |||
| TotalDebt | 78.09M | 58.28M | 38.42M | 39.78M |
| TangibleBookValue | -5.20M | 33.75M | 56.70M | 47.06M |
| InvestedCapital | 97.57M | 105.67M | 107.67M | 98.35M |
| WorkingCapital | 79.30M | 99.21M | 106.35M | 73.86M |
| NetTangibleAssets | -5.20M | 33.75M | 56.70M | 47.06M |
| CapitalLeaseObligations | 2.66M | 3.71M | 4.80M | 5.85M |
| CommonStockEquity | 22.15M | 51.10M | 74.05M | 64.41M |
| TotalCapitalization | 97.57M | 105.67M | 106.36M | 97.55M |
| TotalEquityGrossMinorityInterest | 22.15M | 51.10M | 74.05M | 64.41M |
| StockholdersEquity | 22.15M | 51.10M | 74.05M | 64.41M |
| GainsLossesNotAffectingRetainedEarnings | -122.00K | -119.00K | -119.00K | -119.00K |
| OtherEquityAdjustments | -122.00K | -119.00K | -119.00K | -119.00K |
| RetainedEarnings | -515.36M | -477.90M | -376.74M | -282.87M |
| AdditionalPaidInCapital | 537.46M | 528.96M | 450.79M | 347.37M |
| CapitalStock | 171.00K | 167.00K | 122.00K | 28.00K |
| CommonStock | 171.00K | 167.00K | 122.00K | 28.00K |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 124.30M | 96.16M | 81.53M | 52.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 91.42M | 73.30M | 59.21M | 38.74M |
| OtherNonCurrentLiabilities | 831.00K | 432.00K | 173.00K | 826.00K |
| DerivativeProductLiabilities | 13.76M | 15.68M | 23.13M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 76.83M | 57.18M | 35.91M | 37.91M |
| LongTermCapitalLeaseObligation | 1.41M | 2.61M | 3.60M | 4.78M |
| LongTermDebt | 75.42M | 54.57M | 32.30M | 33.14M |
| CurrentLiabilities | 32.88M | 22.86M | 22.32M | 14.02M |
| CurrentDebtAndCapitalLeaseObligation | 1.25M | 1.10M | 2.51M | 1.87M |
| CurrentCapitalLeaseObligation | 1.25M | 1.10M | 1.20M | 1.07M |
| CurrentDebt | 1.31M | 795.00K | ||
| OtherCurrentBorrowings | 1.31M | 795.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 13.05M | 8.20M | 6.59M | 5.42M |
| PayablesAndAccruedExpenses | 18.57M | 13.57M | 13.22M | 6.74M |
| CurrentAccruedExpenses | 9.95M | 4.62M | 5.44M | 2.45M |
| Payables | 8.62M | 8.95M | 7.78M | 4.28M |
| AccountsPayable | 8.62M | 8.95M | 7.78M | 4.28M |
| TotalAssets | 146.45M | 147.26M | 155.59M | 117.18M |
| TotalNonCurrentAssets | 34.27M | 25.18M | 26.91M | 29.30M |
| OtherNonCurrentAssets | 2.08M | 1.44M | 1.23M | 1.72M |
| GoodwillAndOtherIntangibleAssets | 27.35M | 17.35M | 17.35M | 17.35M |
| OtherIntangibleAssets | 10.00M | |||
| Goodwill | 17.35M | 17.35M | 17.35M | 17.35M |
| NetPPE | 4.84M | 6.39M | 8.33M | 10.22M |
| AccumulatedDepreciation | -1.90M | -1.62M | -1.23M | -724.00K |
| GrossPPE | 6.74M | 8.01M | 9.56M | 10.95M |
| Leases | 228.00K | 228.00K | 228.00K | 228.00K |
| OtherProperties | 4.73M | 6.30M | 7.87M | 9.29M |
| MachineryFurnitureEquipment | 1.78M | 1.49M | 1.47M | 1.43M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 112.17M | 122.08M | 128.68M | 87.88M |
| OtherCurrentAssets | 5.59M | 7.30M | 5.81M | 5.34M |
| PrepaidAssets | 5.34M | |||
| Inventory | 2.82M | 0.00 | ||
| FinishedGoods | 680.00K | 0.00 | ||
| WorkInProcess | 608.00K | 0.00 | ||
| RawMaterials | 1.53M | 0.00 | ||
| Receivables | 1.71M | 562.00K | 1.15M | 747.00K |
| OtherReceivables | 640.00K | 562.00K | 1.15M | 747.00K |
| AccountsReceivable | 1.07M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 102.06M | 114.22M | 121.72M | 81.79M |
| OtherShortTermInvestments | 46.36M | 15.00M | 0.00 | |
| CashAndCashEquivalents | 55.70M | 99.22M | 121.72M | 81.79M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -138.23M | -96.57M | -77.20M | -71.52M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -2.00M | |
| RepaymentOfDebt | 0.00 | -2.06M | -795.00K | 0.00 |
| IssuanceOfDebt | 20.00M | 22.50M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 60.00M | 122.63M | 75.98M |
| CapitalExpenditure | -7.33M | -60.00K | -103.00K | -615.00K |
| InterestPaidSupplementalData | 7.77M | 4.60M | 3.01M | 2.91M |
| EndCashPosition | 56.48M | 100.25M | 123.03M | 83.11M |
| BeginningCashPosition | 100.25M | 123.03M | 83.11M | 80.70M |
| EffectOfExchangeRateChanges | -156.00K | 99.00K | -105.00K | -319.00K |
| ChangesInCash | -43.62M | -22.88M | 40.02M | 2.73M |
| FinancingCashFlow | 20.29M | 88.52M | 117.23M | 74.25M |
| CashFlowFromContinuingFinancingActivities | 20.29M | 88.52M | 117.23M | 74.25M |
| NetOtherFinancingCharges | -631.00K | -4.81M | ||
| ProceedsFromStockOptionExercised | 294.00K | 8.71M | 208.00K | 260.00K |
| NetCommonStockIssuance | 0.00 | 60.00M | 122.63M | 73.98M |
| CommonStockPayments | 0.00 | 0.00 | -2.00M | |
| CommonStockIssuance | 0.00 | 60.00M | 122.63M | 75.98M |
| NetIssuancePaymentsOfDebt | 20.00M | 20.44M | -795.00K | 0.00 |
| NetLongTermDebtIssuance | 20.00M | 20.44M | -795.00K | 0.00 |
| LongTermDebtPayments | 0.00 | -2.06M | -795.00K | 0.00 |
| LongTermDebtIssuance | 20.00M | 22.50M | 0.00 | 0.00 |
| InvestingCashFlow | 66.99M | -14.88M | -103.00K | -615.00K |
| CashFlowFromContinuingInvestingActivities | 66.99M | -14.88M | -103.00K | -615.00K |
| NetOtherInvestingChanges | 105.00M | |||
| NetInvestmentPurchaseAndSale | -30.68M | -14.82M | 0.00 | 0.00 |
| SaleOfInvestment | 26.45M | 2.00M | 0.00 | 0.00 |
| PurchaseOfInvestment | -57.13M | -16.82M | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | -7.00M | 0.00 | 0.00 | |
| PurchaseOfIntangibles | -7.00M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -326.00K | -60.00K | -103.00K | -615.00K |
| PurchaseOfPPE | -326.00K | -60.00K | -103.00K | -615.00K |
| OperatingCashFlow | -130.90M | -96.51M | -77.10M | -70.91M |
| CashFlowFromContinuingOperatingActivities | -130.90M | -96.51M | -77.10M | -70.91M |
| ChangeInWorkingCapital | 2.67M | 344.00K | 5.74M | -1.50M |
| ChangeInOtherCurrentLiabilities | -1.00M | -1.13M | -882.00K | -698.00K |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | -59.00K | |
| ChangeInPayablesAndAccruedExpense | 6.88M | 2.84M | 7.23M | 1.01M |
| ChangeInAccruedExpense | 7.17M | 1.61M | 3.80M | -152.00K |
| ChangeInPayable | -286.00K | 1.23M | 3.42M | 1.17M |
| ChangeInAccountPayable | -286.00K | 1.23M | 3.42M | 1.17M |
| ChangeInPrepaidAssets | 683.00K | -1.37M | -610.00K | -1.75M |
| ChangeInInventory | -2.82M | 0.00 | 0.00 | |
| ChangeInReceivables | -1.07M | 0.00 | 0.00 | |
| ChangesInAccountReceivables | -1.07M | 0.00 | 0.00 | |
| OtherNonCashItems | 1.80M | 2.28M | 2.44M | 2.49M |
| StockBasedCompensation | 8.20M | 8.69M | 5.20M | 6.18M |
| AssetImpairmentCharge | 0.00 | 0.00 | 9.76M | |
| DepreciationAmortizationDepletion | 796.00K | 419.00K | 513.00K | 499.00K |
| DepreciationAndAmortization | 796.00K | 419.00K | 513.00K | 499.00K |
| OperatingGainsLosses | -106.93M | -7.07M | 2.88M | 366.00K |
| GainLossOnInvestmentSecurities | -1.93M | -7.07M | 2.88M | 366.00K |
| NetIncomeFromContinuingOperations | -37.45M | -101.17M | -93.87M | -88.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XFOR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|